Observational studyBMC nephrology2025
The value of transpulmonary thermodilution parameters in predicting hemodynamic instability in intensive care patients undergoing continuous renal replacement therapy.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodynamic instability related to renal replacement therapy (HIRRT) is a serious complication of continuous renal replacement therapy (CRRT) in critically ill patients with acute kidney injury (AKI), significantly increasing mortality risk. The pathophysiology involves complex interactions between cardiac output and systemic vascular resistance. Therefore, identifying early and reliable predictive parameters for HIRRT is clinically crucial.
methodsThis prospective, observational cohort study was conducted in an Internal Medicine Intensive Care Unit between July 2023 and October 2024. Thirty-six patients undergoing CRRT with invasive monitoring via the PiCCO
resultsThe mean age of the patients was 68.1 ± 18.3 years, and 69.4% were male. The most common indication for CRRT was uremic complications (52.8%), and the most frequent comorbidity was hypertension (55.6%). A total of 83.3% of patients were on vasopressor support, and 38.9% were on mechanical ventilation. HIRRT occurred in 55.5% of patients during CRRT, and in 60% of these patients, it developed within the first hour. The HIRRT group had a significantly lower cardiac index (CI) (p = 0.002) and a higher systemic vascular resistance index (SVRI) (p = 0.003). Additionally, the HIRRT group had higher baseline mean arterial pressure (p = 0.015) and baseline diastolic blood pressure (p = 0.003), and a significantly greater total ultrafiltration volume (p = 0.018). Multivariate analysis identified a low CI (p = 0.018) and a high mean arterial pressure (p = 0.031) as independent predictors. ROC analysis revealed that the optimal cut-off value for the mean arterial pressure was 78 mmHg (AUC: 0.759, 95% CI: 0.597-0.922) and that for the CI was 2.61 L/min/m² (AUC: 0.794, 95% CI: 0.642-0.946).
conclusionsLow baseline cardiac index and elevated mean arterial pressure emerged as independent predictors of HIRRT, whereas higher SVRI was significant only in univariate analysis, indicating an association but not independent predictive value. Collectively, these findings suggest that a reduced capacity to increase cardiac output in response to hemodynamic stress, together with alterations in vascular tone regulation, may play a central role in the development of HIRRT. While these parameters may facilitate early identification of high-risk patients and support individualized management strategies, further validation in larger, multicenter cohorts is required. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.